[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,341
  • Shares Outstanding, K 5,336
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,560 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 1.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.69
  • Number of Estimates 2
  • High Estimate $-1.53
  • Low Estimate $-1.84
  • Prior Year $-17.25
  • Growth Rate Est. (year over year) +90.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.08 +22.12%
on 03/24/26
2.77 -8.30%
on 04/13/26
+0.44 (+20.95%)
since 03/23/26
3-Month
1.79 +41.90%
on 03/09/26
5.30 -52.08%
on 02/18/26
-2.14 (-45.73%)
since 01/23/26
52-Week
1.79 +41.90%
on 03/09/26
28.61 -91.12%
on 05/12/25
-23.21 (-90.14%)
since 04/23/25

Most Recent Stories

More News
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication Significant...

MBRX : 2.54 (+1.60%)
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate,...

MBRX : 2.54 (+1.60%)
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile

Access the Moleculin CEO Corner here HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released...

MBRX : 2.54 (+1.60%)
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company History Early Blinded Results Show 40% Remission Rate Across Difficult-to-Treat...

MBRX : 2.54 (+1.60%)
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech,...

MBRX : 2.54 (+1.60%)
Moleculin to Present at 38th Annual ROTH Conference

– Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners HOUSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech,...

MBRX : 2.54 (+1.60%)
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Access the Moleculin CEO Corner here HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released...

MBRX : 2.54 (+1.60%)
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its...

MBRX : 2.54 (+1.60%)
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failures First 45 subjects treated...

MBRX : 2.54 (+1.60%)
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance...

MBRX : 2.54 (+1.60%)

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

3rd Resistance Point 2.67
2nd Resistance Point 2.61
1st Resistance Point 2.55
Last Price 2.54
1st Support Level 2.43
2nd Support Level 2.37
3rd Support Level 2.31

See More

52-Week High 28.61
Fibonacci 61.8% 18.36
Fibonacci 50% 15.20
Fibonacci 38.2% 12.04
Last Price 2.54
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.